A Comprehensive approach for your patients
Evaluate-image

Evaluate

The Meibomian Gland Evaluator™ (MGE) provides standardized, repeatable evaluation of meibomian gland function.

About MGD Meibomian Gland Evaluator
Image-image

Image

LipiScan™ & LipiView II® offer high-definition meibography with Dynamic Meibomian Imaging™.

Product | LipiScan Product | LipiView II
Treat-image

Treat

The LipiFlow® System's drug-free mechanism of action applies precise heat and pressure to remove gland obstructions while protecting delicate structures of the eye.

Product | LipiFlow
Do you know Lipiflow?

Mutual Opportunity

LipiFlow installations are evenly divided between ophthalmology and optometry clinics.

Affordable

Capital and procedure disposable prices have been reduced by up to 50% to make the LipiFlow system more accessible.*

*Pricing adjustments made in 2015 and 2016.

WIDELY AVAILABLE

LipiFlow is available in more than 850 practice locations in the US and Canada as of October 2017.

Proven treatment for MGD
Lipiflow Home Image

UNIQUE

The LipiFlow System is a cleared medical device shown to improve gland function.

EFFECTIVE

86% of patients with a single LipiFlow procedure showed mean improvement in meibomian gland function and dry eye symptoms.1

DRUG-FREE

The LipiFlow System uses a drug-free mechanism of action.

BREAKTHROUGH

Proprietary VTP™ Technology uniquely applies heat and therapeutic motion to improve gland function.

Learn More About Lipiflow

The TearScience Advantage

Learn about the progression of MGD and how the LipiFlow System applies heat and pressure directly to the inner lid where the meibomian glands are located to clear obstructed glands

Learn More About Lipiflow

Evaluate Gland Function on Every Patient

The MGE is an efficient, cost effective device to determine function and track progression and treatment response in routine eye exams.

Learn More About The MGE

Order an MGE for your practice now »
The DMI Difference
DMI difference image
  • Dynamic Meibomian Imaging (DMI) technology is available with LipiScan and LipiView II

  • Simultaneously employs non-contact surface illumination and high-definition transillumination

  • Provides accurate visualization of gland morphology

See DMI in Action

Why Treat MGD?

Prevalent

MGD affects approximately 86% of dry eye patients2

Widespread

Over 340 million people worldwide suffer from dry eye3

More Information on MGD

References

1. Blackie CA, Coleman CA, Holland EJ. The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. Clin Ophthal. 2016;10:1385-1396.

2. Lemp, M. A., Crews, L. A., Bron, A. J., Foulks, G. N., & Sullivan, B. D. (2012). Distribution of Aqueous-Deficient and Evaporative Dry Eye in a Clinic-Based Patient Cohort. Cornea, 31(5), 472-478. doi:10.1097/ico.0b013e318225415a

3. Market Scope 2016 Dry Eye Report

Request a Quote
Thank You!

You will be contacted by TearScience Customer Service within 3 business days.

For more information

Contact Us


OR


(877) 266-4543